Related Topics News -

     
 Detail   |   Print 
     
和譽泛致癌驅動基因抑制劑ABSK211一期臨床完成首例患者給藥
2026-08-31T  
《業績》和譽中期虧損1.93億人民幣 盈轉虧
2026-08-25T  
和譽ABSK211獲國家藥監局批准新藥臨床試驗申請
2026-08-19T  
和譽抑制劑ABSK211新藥臨床試驗申請獲FDA批准
2026-07-13T  
《大行》瑞銀降和譽目標價至17.5元 重申「買入」評級
2026-07-08T  
和譽與阿斯利康戰略合作 推進NSCLC臨床研究
2026-07-02T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.